ADVERTISEMENT
Podcasts
iFCG Regimen Effective for Young, Fit Patients With IGHV-Mutated CLL
02/07/2020
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, discusses results from a phase 2 study exploring a treatment regimen consisting of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for patients with IGHV-mutated CLL.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement